Key events, in time order
First-in-class investigational therapy for pediatric Tourette syndrome gets priority review, advancing pipeline
None yet
None yet
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
Teva makes and sells generic and specialty drugs, from multiple sclerosis treatments to asthma inhalers, across the globe. Think of it as a pharmacy shelf staple, offering cheaper alternatives and branded meds.
Teva's money comes from selling a wide range of drugs, with gross margins around 52% and net margins near 4% in 2025. Revenue is recurring from ongoing prescriptions, though patent expirations can cause swings.
Teva's scale in generics and complex drugs like Copaxone creates some barrier, but competition from Mylan and Sandoz, plus pricing pressure, weakens it. The moat is eroding as these rivals gain ground.
Sell (sector percentile 16) — value B, growth F, profitability B, momentum B-, revisions C. Updated daily, sector-relative, identical for every user.
